Literature DB >> 27095143

What to Do With "Moderate" Reliability and Validity Coefficients?

Marcel W Post1.   

Abstract

Clinimetric studies may use criteria for test-retest reliability and convergent validity such that correlation coefficients as low as .40 are supportive of reliability and validity. It can be argued that moderate (.40-.60) correlations should not be interpreted in this way and that reliability coefficients <.70 should be considered as indicative of unreliability. Convergent validity coefficients in the .40 to .60 or .40 to .70 range should be considered as indications of validity problems, or as inconclusive at best. Studies on reliability and convergent should be designed in such a way that it is realistic to expect high reliability and validity coefficients. Multitrait multimethod approaches are preferred to study construct (convergent-divergent) validity.
Copyright © 2016 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Keywords:  Outcome assessment (health care); Psychometrics; Rehabilitation; Validation studies as topic

Mesh:

Year:  2016        PMID: 27095143     DOI: 10.1016/j.apmr.2016.04.001

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  18 in total

1.  Responsiveness and Minimally Important Differences for 4 Patient-Reported Outcomes Measurement Information System Short Forms: Physical Function, Pain Interference, Depression, and Anxiety in Knee Osteoarthritis.

Authors:  Augustine C Lee; Jeffrey B Driban; Lori Lyn Price; William F Harvey; Angie Mae Rodday; Chenchen Wang
Journal:  J Pain       Date:  2017-05-10       Impact factor: 5.820

2.  Test-Retest Reliabilities of Four Tactic-first Sexual Violence History Questionnaires.

Authors:  RaeAnn E Anderson; Monica Garcia; Douglas L Delahanty
Journal:  Psychol Violence       Date:  2021-05-06

3.  Critical review of the use of the Rorschach in European courts.

Authors:  Igor Areh; Fanny Verkampt; Alfred Allan
Journal:  Psychiatr Psychol Law       Date:  2021-05-26

4.  Assessing Language in Unstructured Conversation in People With Aphasia: Methods, Psychometric Integrity, Normative Data, and Comparison to a Structured Narrative Task.

Authors:  Marion C Leaman; Lisa A Edmonds
Journal:  J Speech Lang Hear Res       Date:  2021-10-07       Impact factor: 2.674

5.  A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A CLINICAL PRACTICE GUIDELINE.

Authors:  Jennifer L Moore; Kirsten Potter; Kathleen Blankshain; Sandra L Kaplan; Linda C OʼDwyer; Jane E Sullivan
Journal:  J Neurol Phys Ther       Date:  2018-07       Impact factor: 3.649

6.  Convergent Validity and Responsiveness of the SULCS.

Authors:  Jayme S Knutson; Amy S Friedl; Kristine M Hansen; Terri Z Hisel; Mary Y Harley
Journal:  Arch Phys Med Rehabil       Date:  2018-08-24       Impact factor: 3.966

Review 7.  Measurement of Physical Activity and Energy Expenditure in Wheelchair Users: Methods, Considerations and Future Directions.

Authors:  Tom E Nightingale; Peter C Rouse; Dylan Thompson; James L J Bilzon
Journal:  Sports Med Open       Date:  2017-03-01

8.  Kinematics and temporospatial parameters during gait from inertial motion capture in adults with and without HIV: a validity and reliability study.

Authors:  Karina Berner; John Cockcroft; Quinette Louw
Journal:  Biomed Eng Online       Date:  2020-07-24       Impact factor: 2.819

9.  Reliability and Validity of the Geriatric Depression Scale in Italian Subjects with Parkinson's Disease.

Authors:  Perla Massai; Francesca Colalelli; Julita Sansoni; Donatella Valente; Marco Tofani; Giovanni Fabbrini; Andrea Fabbrini; Michela Scuccimarri; Giovanni Galeoto
Journal:  Parkinsons Dis       Date:  2018-08-01

10.  Psychometric evaluation of the Persian version of the Doloplus-2 (P-Doloplus-2) scale in elderly with dementia

Authors:  Mohammad Zare; Zahra Tagharrobi; Khadijeh Sharifi; Zahra Sooki; Javad Abolhasani
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.